Cargando…

First results of hormone receptors' status in Malagasy women with invasive breast cancer

INTRODUCTION: Breast cancer is the most common malignancy tumor amongst Malagasy women registered at the pathology unit of the “Institut Pasteur de Madagascar”. In Madagascar, there is no laboratory practicing hormone receptors' status on these tumors. Until now no study about hormone receptors...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasiniatsy, Nomeharisoa Rodrigue Emile, Vololonantenaina, Clairette Raharisolo, Rabarikoto, Hary Fanambinantsoa, Razafimanjato, Narindra, Ranoharison, Hasina Dina, Rakotoson, Joelson Lovaniaina, Samison, Luc Hervé, Rafaramino, Florine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119455/
https://www.ncbi.nlm.nih.gov/pubmed/25120866
http://dx.doi.org/10.11604/pamj.2014.17.153.3045
Descripción
Sumario:INTRODUCTION: Breast cancer is the most common malignancy tumor amongst Malagasy women registered at the pathology unit of the “Institut Pasteur de Madagascar”. In Madagascar, there is no laboratory practicing hormone receptors' status on these tumors. Until now no study about hormone receptors' status of Malagasy women with invasive breast cancer was performed. So it will be the first study talking about this topic. The aim of this study was to determine hormone receptors' status in Malagasy women with invasive breast cancer. METHODS: This retrospective and descriptive study was based on patients' medical files from 2009 to 2011. It included all invasive breast cancer diagnosed in Malagasy women at the pathology laboratory located at the “Institut Pasteur de Madagascar”, in Antananarivo. Along this period this laboratory has sent paraffin blocks of invasive breast carcinoma in two pathological laboratories in France. RESULTS: We collected 77 cases of invasive breast cancer along this period. The mean age was 48.8 +/- 10.7, ranging from 26 years to 70 years. There were 46.8 % (n = 36) women with progesterone receptor positive (PR+), 53.2 % (n = 41) with progesterone receptor negative (PR-). For the estrogen receptor, 61.0 % (n = 47) were positive and 36.4 % (n = 28) were negative. ER+/PR+ represented 44.2 % (n = 34); ER-/PR- 33.8 % (n = 26); ER +/ PR- 16.8 % (n = 13); ER-/PR+ and ER-/PR- represented respectively 2.6 % (n = 2). CONCLUSION: Patients in our study had more important rate of ER-, PR- and a less important rate of ER+/PR+, PR+. These results suggest that more study related to Hormone Receptor profile should be conducted in Malagasy women with breast cancer.